期刊文献+

抗前列腺癌药物恩杂鲁胺有关物质的合成

Synthesis of related substance of anti-prostate cancer drug enzalutamide
原文传递
导出
摘要 目的合成抗前列腺癌药恩杂鲁胺的3个有关物质。方法 2-(3-氟-4-(甲氧甲酰基)苯基氨基)-2-甲基丙酸甲酯与4-氰基-3-三氟甲基苯异硫氰酸酯反应制得中间体3-(4-氰基-3-三氟甲基苯基)-1-(3-氟-4-(甲氧基甲酰)苯基)-5,5-二甲基-2-硫代咪唑啉-4-酮,该中间体与氢氧化钠水溶液发生皂化反应制得杂质4-(3-(4-氰基-3-(三氟甲基)苯基)-5,5-二甲基-4-氧代-2-硫代咪唑烷-1-基)-2-氟苯甲酸(Ⅰ);该中间体与氨水反应制得杂质4-(3-(4-氰基-3-(三氟甲基)苯基)-5,5-二甲基-4-氧代-2-硫代咪唑烷-1-基)-2-氟苯甲酰胺(Ⅱ)。2-(4-(甲氧甲酰基)苯基氨基)-2-甲基丙酸甲酯与4-氰基-3-三氟甲基苯异硫氰酸酯反应制得中间体3-(4-氰基-3-三氟甲基苯基)-1-(4-(甲氧基甲酰)苯基)-5,5-二甲基-2-硫代咪唑啉-4-酮,该中间体与甲胺水溶液反应制得杂质4-(3-(4-氰基-3-(三氟甲基)苯基)-5,5-二甲基-4-氧代-2-硫代咪唑烷-1-基)-N-甲基苯甲酰胺(Ⅲ)。结果与结论合成的3个有关物质的结构经MS、1H-NM R谱确证,HPLC法检测其纯度分别为96.85%、97.61%、99.72%。Ⅰ、Ⅱ、Ⅲ可作为恩杂鲁胺质量控制的杂质对照品。 For the purpose of quality control of enzalutamide,three related substances were synthesized and characterized,the impurities 2-fluoro-4-( 1,1-dimethylcyanomethyl) amino-benzonic acid( Ⅰ) and 2-fluoro-4-( 1,1-dimethylcyanomethyl) aminobenzonamide( Ⅱ) were synthesized via the same route of enzalutamide but changing the different nucleophilic reagents of sodium hydroxide solution or ammonium hydroxide. The impurity N-methyl-4-( 1,1-dimethylcyanomethyl) aminobenzonamide( Ⅲ) was also synthesized by the same route but using different starting materials. The structures of three impurities of enzalutamide were tested by MS and1H-NMR spectra,the purities( 96. 85%,97. 61%,99. 72%) were determined by HPLC analysis,which also can be used as the reference substances of the related substances in the quality control of enzalutamide.
出处 《中国药物化学杂志》 CAS CSCD 2016年第5期406-408,412,共4页 Chinese Journal of Medicinal Chemistry
关键词 恩杂鲁胺 前列腺癌 有关物质 合成 enzalutamide prostate cancer related substances synthesis
  • 相关文献

参考文献3

二级参考文献32

  • 1Siegel R,Naishadham D,Jemal A.Cancer statistics,2012[J].CA Cancer J Clin,2012,62(1):10-29.
  • 2Huggins C,Hodges C V.Studies on prostatic cancer.I.The effect of castration,of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate[J].1941.J Urol.2002,167(2Pt2 ):948-951;discussion 952.
  • 3Huggins C.The hormone-dependent cancers[J].JAMA,1963,186:481-483.
  • 4Perlmutter M A,Lepor H.Androgen deprivation therapy in the treatment of advanced prostate cancer[J].Rev Urol,2007,9(Suppl 1):S3-S8.
  • 5Harris W P,Mostaghel E A,Nelson P S,et al.Androgen deprivation therapy:progress in understanding mechanisms of resistance and optimizing androgen depletion[J].Nat Clin Pract Urol,2009,6(2):76-85.
  • 6Crawford E D,Eisenberger M A,McLeod D G,et al.A controlled trial of leuprolide with and without flutamide in prostatic carcinoma[J].N Engl J Med,1989,321(7):419-424.
  • 7Eisenberger M A,Blumenstein B A,Crawford E D,et al.Bilateral orchiectomy with or without flutamide for metastatic prostate cancer[J].N Engl J Med,1998,339(15):1036-1042.
  • 8Crawford E D.Combined androgen blockade[J].Urology,1989,34(4Suppl):22-26;discussion 46-56.
  • 9Walsh P C.Immediate versus deferred treatment for advanced prostatic cancer:initial results of the Medical Research Council trial.The Medical Research Council Prostate Cancer Working Party Investigators Group[J].J Urol,1997,158(4):1623-1624.
  • 10Messing E M,Manola J,Sarosdy M,et al.Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer[J].N Engl J Med,1999,341(24):1781-1788.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部